U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. News & Events
  3. FDA Meetings, Conferences and Workshops
  4. May 10, 2022: Conversations on Cancer: “A Global Dialogue on Ovarian Cancer”, Meeting Information; #ConversationsOnCancer - 05/10/2022
  1. FDA Meetings, Conferences and Workshops

Webcast | Virtual

Event Title
May 10, 2022: Conversations on Cancer: “A Global Dialogue on Ovarian Cancer”, Meeting Information; #ConversationsOnCancer
May 10, 2022

Date:
May 10, 2022
Organized By:
Organizer

Twitter: #ConversationsOnCancer

#OCEProjectCommunity

#NothingWillStopUs

Sponsored by the U.S. Food & Drug Administration (FDA)

Featured Speakers:

Annie Ellis, Ovarian Cancer Survivor| Research Advocate

Gwynn Ison, MD, Acting Team Leader, Division of Oncology 1, Office of Oncologic Diseases, Office of New Drugs, CDER

Clara MacKay, MA, Chief Executive Officer, World Ovarian Cancer Coalition

Tracy Moore, LCSW, Oncology Social Worker, Patient Support (Consultant), Ovarian Cancer Research Alliance

Richard Pazdur, MD, Director, Oncology Center of Excellence, FDA

Kimberly Richardson, Ovarian Cancer Survivor | Research Advocate, Black Cancer Collaborative

Moderator: Rea Blakey, Associate Director for External Outreach and Engagement, Oncology Center of Excellence, FDA

Registration required to attend: https://www.surveymonkey.com/r/ZCJTDHT

Background:

The Oncology Center of Excellence Conversations On Cancer public panel discussion series is observing World Ovarian Cancer Day. Join this 1-hour informal panel discussion exploring personal perspectives from survivors, clinicians, and patient advocates on the impact of ovarian cancer. Panelists will discuss global challenges of ovarian cancer drug development, address the importance of clinical trial participation, and discuss barriers for patients’ access to clinical trials.

The discussion will also address successful strategies in educating, recruiting and following up with patients about clinical trials. Other discussion topics will include defining clinical benefit and tolerability of new cancer therapies for maintenance treatment of ovarian cancer, when patients receive a treatment to help keep cancer from coming back after it has disappeared following the initial therapy.

Webcast Information:

A free-of-charge webcast of this public panel discussion will be provided. Registration for the webcast is required at the link above.

FDA plans to post archived webcasts of the Conversations on Cancer program at: https://www.fda.gov/about-fda/oncology-center-excellence/conversations-cancer

Contact:

For any inquiries regarding this program, please send an email to: OCE-Engagement@fda.hhs.gov

Back to Top